Abivax (AAVXF) Operating Expenses (2022 - 2026)

Abivax has reported Operating Expenses for 5 years, with the latest figure at -$67.4 million in Q1 2026.

• On a quarterly basis, Operating Expenses fell 32.96% year-over-year to -$67.4 million in Q1 2026; TTM through Mar 2026 was -$301.9 million, a 49.69% decrease from a year earlier, with the FY2025 full-year figure at -$291.7 million, down 47.23% from the prior year.
• Operating Expenses was -$67.4 million for Q1 2026 at Abivax, up from -$83.9 million in the prior quarter.
• The five-year high for Operating Expenses was -$56.93 in Q4 2022, with the low at -$96.7 million in Q3 2025.
• Average Operating Expenses over 5 years is -$50.3 million, with a median of -$50.7 million recorded in 2025.
• The sharpest annual moves came in 2024 and 2025: Operating Expenses tumbled 37250245.96% in 2024, then decreased 1.76% in 2025.
• Over 5 years, Operating Expenses stood at -$56.93 in 2022, then tumbled by 137.38% to -$135.14 in 2023, then sank by 37250245.96% to -$50.3 million in 2024, then tumbled by 66.7% to -$83.9 million in 2025, then gained by 19.67% to -$67.4 million in 2026.
• The last three Operating Expenses figures came in at -$67.4 million (Q1 2026), -$83.9 million (Q4 2025), and -$96.7 million (Q3 2025), per Business Quant data.